不良反应等“尚不明确”的中成药或将被调出中国医保目录

Core Insights - The adjustment of China's medical insurance drug catalog for 2026 will focus on traditional Chinese medicines (TCM) with unclear contraindications, adverse reactions, and precautions in their instructions [1][2] - The principle of supporting innovation in medical insurance remains unchanged, with a dynamic adjustment approach that emphasizes the clinical value of innovations [1] - Drugs that have been clinically replaced, have uncertain clinical effects, or have not been produced for a long time will be prioritized for removal from the catalog [1] Group 1 - The National Medical Insurance Administration indicated that TCM with "unclear" items in their instructions may be removed from the insurance catalog [1] - The adjustment process will maintain a balance of adding and removing drugs, focusing on those that do not meet current clinical needs [1] - The recent regulations from the National Medical Products Administration state that any TCM with unclear contraindications, adverse reactions, or precautions will not be re-registered after July 1, 2026, potentially leading to a significant exit of TCM from the market [1] Group 2 - TCM applications for inclusion in the insurance catalog will face challenges if their instructions contain "unclear" items [2] - Existing TCM in the current catalog may also be removed if they have unresolved issues in their instructions, aligning with national safety and rational medication requirements [2]